poisar

Stocks · News reference

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

Vandana Singh

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABTBBNXDXCMMMEDPODDTNDM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Reuben Gregg Brewer

    Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside

    Ken Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.

    ABBVAMJBJPMJPMPCJPMPD
  3. Stefon Walters

    1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

    The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

    SCHDMRKAMGNABTKO